Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approv...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events. The following videos, which include CEO interviews, are now available on the Company’s website at the bottom of the Welcome page: Jun 28, 20...
ServisFirst Bancshares, Inc. Ranks Fifth Among Top Publicly Traded Banks with between $10 Billion to $50 Billion in Assets The Sole Alabama-Based Institution in the Top Ten BIRMINGHAM, Ala., July 28, 2025 (GLOBE NEWSWIRE) -- , a subsidiary of ServisFirst Bancshares (NYSE:SFBS), is pleased to announce they have ranked fifth in the top publicly traded banks with between $10 billion to $50 billion in assets, according to annual list of top-performing banks, based on year-end 2024 data. Compiled by using data and regulatory filings, the ranking recognizes banks delivering exceptional fin...
ServisFirst Bancshares, Inc. Announces Results For Second Quarter of 2025 BIRMINGHAM, Ala., July 21, 2025 (GLOBE NEWSWIRE) -- ServisFirst Bancshares, Inc. (NYSE: SFBS), today announced earnings and operating results for the quarter ended June 30, 2025. Second Quarter 2025 Highlights: Diluted earnings per share of $1.12 for the quarter. Adjusted diluted earnings per share of $1.21, up 27% from the second quarter of 2024.Net interest margin improved to 3.10% in the second quarter from 2.92% in the first quarter. Adjusted net interest margin was 3.06% in the second quarter.Loans grew by $3...
ServisFirst Bancshares, Inc. to Announce Second Quarter 2025 Financial Results July 21st BIRMINGHAM, Ala., June 30, 2025 (GLOBE NEWSWIRE) -- ServisFirst Bancshares, Inc. (NYSE: SFBS) is scheduled to announce earnings and operating results for the quarter ended June 30, 2025 on July 21, 2025 at 4 p.m. ET. The news release will be available at . ServisFirst Bancshares, Inc. will host a live audio webcast to discuss earnings and results on Monday, July 21, 2025 beginning at 5:15 p.m. ET. The audio webcast can be accessed at . A replay of the call will be available until July 31, 2025. Abou...
ServisFirst Bancshares, Inc. Declares Second Quarter Cash Dividend BIRMINGHAM, Ala., June 17, 2025 (GLOBE NEWSWIRE) -- ServisFirst Bancshares, Inc., (NYSE: SFBS) (“ServisFirst”), the holding company for ServisFirst Bank, today announces: At a meeting held on June 16, 2025, its Board of Directors declared a quarterly cash dividend of $0.335 per share, payable on July 9, 2025, to stockholders of record as of July 1, 2025. About ServisFirst Bancshares, Inc. ServisFirst Bancshares, Inc. is a bank holding company based in Birmingham, Alabama. Through its subsidiary ServisFirst Bank, Servis...
Greenwich LifeSciences Provides Global Update on FLAMINGO-01 STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trendi...
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the preliminary immune response data from ...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from dat...
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label safety data. FLAMINGO-01 Data Safety Monitoring Board (DSMB) The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to c...
A director at ServisFirst Bancshares Inc sold 18,000 shares at 88.680USD and the significance rating of the trade was 84/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary rev...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.